Kymera Therapeutics to Participate in Upcoming June Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St set to open higher after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Kymera Therapeutics (KYMR) PT Raised to $60 at Citi
June 2, 2025 2:09 PM EDTCiti analyst Geoff Meacham raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $60.00 (from $52.00) while maintaining a Buy rating.
The analyst comments "Today's positive phase 1 healthy volunteer data for KT-621 (STAT6 degrader) de-risks the asset in our view and underscores the... More
Citi Reiterates Buy Rating on Kymera Therapeutics (KYMR)
June 2, 2025 8:04 AM EDTCiti analyst Geoff Meacham reiterated a Buy rating and $52.00 price target on Kymera Therapeutics (NASDAQ: KYMR).
The analyst comments "Earlier today, Kymera presented positive phase 1 results of its STAT-6 degrader (KT-621). The drug achieved exceptional STAT6 degradation, exceeding 90% mean degradation in blood... More
